#astrazeneca

#astrazeneca

British pharmaceutical giant AstraZeneca has pledged a $15 billion investment in China by 2030, aiming to expand its medicines manufacturing and research and development capabilities. The announcement, made on Thursday during Prime Minister Keir Starmer's visit to Beijing, marks the largest deal of his trip as Britain seeks to strengthen ties with China amid strained relations with Washington. Prime Minister Starmer welcomed the investment, stating: "AstraZeneca's expansion and leadership in China will help the British manufacturer continue to grow - supporting thousands of UK jobs."

The company says its new harmonised listing structure will merely make it easier for those US funds that aren't allowed to own American depositary receipts (ADRs, a wrapper provided by a handful of banks for US investors) to get their hands on full-fat AstraZeneca stock. A global listing for global investors in a global company, as the cheerful corporate spin put it. But this definitely is not a moment to accentuate the positive.

The grass is not always greener on US stock markets

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, responding to President Trump's tariff policy.

AstraZeneca's $50bn investment aims to establish a new drug manufacturing facility in Virginia and expand research and development across various US states, highlighting a significant commitment to US operations in response to looming tariffs on foreign pharmaceuticals.

Sir Pascal Soriot has repeatedly highlighted the need for Europe to enhance its incentives for new medicines, warning that jobs could relocate to the US if these conditions remain unchanged.